Improving risk assessment

Science Translational Medicine

Volumn 4, Issue 159, 2012, Pages

  Dambach, Donna M ^a   Uppal, Hirdesh ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENOTOXICITY; MICROFLUIDICS; NANOTECHNOLOGY; NATIONAL HEALTH ORGANIZATION; PHARMACOGENOMICS; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; UNITED STATES;

CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; HUMANS; LAB-ON-A-CHIP DEVICES; MODELS, BIOLOGICAL; RISK ASSESSMENT;

EID: 84869103557     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3003497     Document Type: Review

References (30)

1. B. Munos, Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8, 959-968 (2009).
2. D. Schuster, C. Laggner, T. Langer, Why drugs fail - A study on side eff ects in new chemical entities. Curr. Pharm. Des. 11, 3545-3559 (2005).
3. J. Arrowsmith, Trial watch: Phase II failures: 2008-2010. Nat. Rev. Drug Discov. 10, 328-329 (2011).
4. J. Arrowsmith, Trial watch: Phase III and submission failures: 2007-2010. Nat. Rev. Drug Discov. 10, 87 (2011).
5. Food and Drug Administration, Challenges and opportunities report, Innovation or stagnation: Challenge and opportunity on the critical path to new medical products (2004). http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm.
6. F. S. Collins, Reengineering translational science: The time is right. Sci. Transl. Med. 3, 90cm17 (2011).
7. P. Greaves, A. Williams, M. Eve, First dose of potential new medicines to humans: How animals help. Nat. Rev. Drug Discov. 3, 226-236 (2004).
8. Defense Advanced Research Projects Agency, Broad agency announcement: Microphysiological systems (2011). https://www.fbo.gov/index?s= opportunity&mode=form&id=956b160c42aaa386cf5762f12c21be9f&tab= core&-cview=0.
9. D. Huh, G. A. Hamilton, D. E. Ingber, From 3D cell culture to organs-on-chips. Trends Cell Biol. 21, 745-754 (2011).
10. D. Huh, B. D. Matthews, A. Mammoto, M. Montoya-Zavala, H. Y. Hsin, D. E. Ingber, Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 (2010).
11. K. Viravaidya, A. Sin, M. L. Shuler, Development of a microscale cell culture analog to probe naphthalene toxicity. Biotechnol. Prog. 20, 316-323 (2004).
12. F. Sonntag, N. Schilling, K. Mader, M. Gruchow, U. Klotzbach, G. Lindner, R. Horland, I. Wagner, R. Lauster, S. Howitz, S. Hoff mann, U. Marx, Design and prototyping of a chip-based multi-micro-organoid culture system for substance testing, predictive to human (substance) exposure. J. Biotechnol. 148, 70-75 (2010).
13. M. L. Stephens, C. Barrow, M. E. Andersen, K. Boekelheide, P. L. Carmichael, M. P. Holsapple, M. Lafranconi, Accelerating the development of 21st-century toxicology: Outcome of a Human Toxicology Project Consortium workshop. Toxicol. Sci. 125, 327-334 (2012).
14. M. B. Esch, T. L. King, M. L. Shuler, The role of body-on-a-chip devices in drug and toxicity studies. Annu. Rev. Biomed. Eng. 13, 55-72 (2011).
15. Y. Imura, K. Sato, E. Yoshimura, Micro total bioassay system for ingested substances: Assessment of intestinal absorption, hepatic metabolism, and bioactivity. Anal. Chem. 82, 9983-9988 (2010).
16. M. Wind, W. S. Stokes, Developing performance standards to expedite validation of innovative and improved test methods. ALTEX 27, 97-102 (2010). http://iccvam.niehs.nih.gov/meetings/7thWC/ms/rBS10-Wind1.pdf.
17. J. A. Kramer, J. E. Sagartz, D. L. Morris, The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat. Rev. Drug Discov. 6, 636-649 (2007).
18. Food and Drug Administration, Guidance for the industry. Drug-induced liver injury: Premarketing clinical evaluation. www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/default.htm (2009).
19. J. Uetrecht, Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47, 513-539 (2007).
20. C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, N. Chalasani, Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 47, 2003-2009 (2008).
21. C. Lammert, E. Bjornsson, A. Niklasson, N. Chalasani, Oral medications with signifi cant hepatic metabolism at higher risk for hepatic adverse events. Hepatology 51, 615-620 (2010).
22. D. A. Smith, E. F. Schmid, Drug withdrawals and the lessons within. Curr. Opin. Drug Discov. Devel. 9, 38-46 (2006).
23. P. D. Leeson, B. Springthorpe, The infl uence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Discov. 6, 881-890 (2007).
24. Food and Drug Administration, E14: "The Clinical Evaluation of QT/QTc Interval Prolongation Potential For NonAntiarrhythmic Drugs. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf (2005).
25. J. Koerner, Correlations between nonclinical and clinical QT data in FDA. The Toxicol. 126, 366 (2012). http://www.hesiglobal.org/i4a/pages/Index.cfm? pageID=3417.
26. H. G. Laverty, C. Benson, E. J. Cartwright, M. J. Cross, C. Garland, T. Hammond, C. Holloway, N. McMahon, J. Milligan, B. K. Park, M. Pirmohamed, C. Pollard, J. Radford, N. Roome, P. Sager, S. Singh, T. Suter, W. Suter, A. Trafford, P. G. A. Volders, R. Wallis, R. Weaver, M. York, J. P. Valentin, How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines? Br. J. Pharmacol. 163, 675-693 (2011).
27. The Clinical Evaluation of QT/QTc Interval Prolongation Potential For Non-Antiarrhythmic Drugs, http://www.fda.gov/downloads/RegulatoryInformation/ Guidances/ucm129357.pdf.
28. R. J. Fontana, P. B. Watkins, H. L. Bonkovsky, N. Chalasani, T. Davern, J. Serrano, J. Rochon; DILIN Study Group, Drug-Induced Liver Injury Network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 32, 55-68 (2009).
29. E. L. Kwak, Y.-J. Bang, D. R. Camidge, A. T. Shaw, B. Solomon, R. G. Maki, S.-H. I. Ou, B. J. Dezube, P. A. Jänne, D. B. Costa, M. Varella-Garcia, W.-H. Kim, T. J. Lynch, P. Fidias, H. Stubbs, J. A. Engelman, L. V. Sequist, W. W. Tan, L. Gandhi, M. Mino-Kenudson, G. C. Wei, S. M. Shreeve, M. J. Ratain, J. Settleman, J. G. Christensen, D. A. Haber, K. Wilner, R. Salgia, G. I. Shapiro, J. W. Clark, A. J. Iafrate, Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
30. P. B. Chapman, A. Hauschild, C. Robert, J. B. Haanen, P. Ascierto, J. Larkin, R. Dummer, C. Garbe, A. Testori, M. Maio, D. Hogg, P. Lorigan, C. Lebbe, T. Jouary, D. Schadendorf, A. Ribas, S. J. O'Day, J. A. Sosman, J. M. Kirkwood, A. M. M. Eggermont, B. Dreno, K. Nolop, J. Li, B. Nelson, J. Hou, R. J. Lee, K. T. Flaherty, G. A. McArthur; BRIM-3 Study Group, Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).